International Journal of COPD, 2015 Anoop Prakash,1 K Suresh Babu,2 Jaymin B Morjaria1,31Department of Respiratory Medicine, Castle Hill Hospital, Cottingham, 2Department of Respiratory Medicine, Queen Alexandra Hospital, Cosham, Portsmouth, 3Department of Academic Respiratory Medicine ...
Jaymin B Morjaria
exaly +3 more sources
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan [PDF]
International Journal of COPD, 2015 Nobuyuki Horita, Takeshi Kaneko Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan Abstract: Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device ...
Horita N, Kaneko T
doaj +3 more sources
Efficacy and safety of topical glycopyrronium bromide in treating axillary hyperhidrosis: systematic review and meta-analysis [PDF]
Scientific ReportsBackground Hyperhidrosis (HH), characterized by excessive sweating, poses a significant challenge to patients’ quality of life. This meta-analysis evaluates the safety and efficacy of topical glycopyrronium bromide (GBP) in treating primary hyperhidrosis,
Amr Elrosasy +9 more
doaj +2 more sources
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide [PDF]
International Journal of COPD, 2018 Marco Mantero,1,2 Dejan Radovanovic,3 Pierachille Santus,3 Francesco Blasi1,2 1Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; 2Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis ...
Mantero M +3 more
doaj +2 more sources
NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY [PDF]
Медицинский совет, 2016 The therapy by fixed combinations, LABA/LAACD on the basis of indacaterol and glycopyrronium bromide is characterized by a high clinical efficacy compared to monocomponents of the product, tiotropium, and a fixed combination of LABA/iCGS.
S. N. AVDEEV
doaj +2 more sources
A cost-effectiveness analysis comparing single-inhaler extrafine beclomethasone/formoterol/glycopyrronium bromide against other SITTs in adult patients with uncontrolled asthma in England [PDF]
Health Economics ReviewBackground In patients with asthma uncontrolled by a medium or high-strength (MS/HS) inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA), according to Global Initiative for Asthma (GINA) guidelines, a maintenance therapy option is the ...
Ioanna Vlachaki +6 more
doaj +2 more sources
Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide [PDF]
International Journal of COPD, 2017 Dave Singh,1 Massimo Corradi,2 Monica Spinola,3 Alberto Papi,4 Omar S Usmani,5 Mario Scuri,3 Stefano Petruzzelli,3 Jørgen Vestbo1 1Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK; 2Department of ...
Singh D +7 more
doaj +2 more sources
Therapeutic Advances in Respiratory Disease, 2015 The international guidelines on chronic obstructive pulmonary disease (COPD) recommend inhaled bronchodilators for maintenance treatment of the disease. These drugs include β2-agonists and muscarinic antagonists, which are both available as short-acting ...
Erminia Ridolo +4 more
doaj +2 more sources
Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
Therapeutics and Clinical Risk Management, 2013 Anthony D'UrzoDepartment of Family and Community Medicine, University of Toronto, Toronto, ON, CanadaAbstract: Progressive airflow limitation is a hallmark feature of chronic obstructive pulmonary disease (COPD) that ultimately leads to ...
D’Urzo A
doaj +1 more source
Efficacy of single-inhaler triple therapies for chronic obstructive pulmonary disease: a systematic review and network meta-analysis [PDF]
BMC Pulmonary MedicineAim This study aims to systematically evaluate which single-inhaler triple therapy (inhaled corticosteroids [ICS], long-acting β2-agonists [LABA], and long-acting muscarinic antagonists [LAMA]) is safer and more effective for treating chronic obstructive
Yu Zhang, Pei Zhao, Yudong Zhang
doaj +2 more sources